Literature DB >> 32958583

Proof of Concept of a Personalized Genetic Risk Tool to Promote Smoking Cessation: High Acceptability and Reduced Cigarette Smoking.

Alex T Ramsey1, Jessica L Bourdon2, Michael Bray2, Amelia Dorsey2, Maia Zalik2, Amanda Pietka2, Patricia Salyer2, Li-Shiun Chen2, Timothy B Baker3, Marcus R Munafò4,5, Laura J Bierut2.   

Abstract

Relatively little is known about the possible effects of personalized genetic risk information on smoking, the leading preventable cause of morbidity and mortality. We examined the acceptability and potential behavior change associated with a personalized genetically informed risk tool (RiskProfile) among current smokers. Current smokers (n = 108) were enrolled in a pre-post study with three visits. At visit 1, participants completed a baseline assessment and genetic testing via 23andMe. Participants' raw genetic data (CHRNA5 variants) and smoking heaviness were used to create a tailored RiskProfile tool that communicated personalized risks of smoking-related diseases and evidence-based recommendations to promote cessation. Participants received their personalized RiskProfile intervention at visit 2, approximately 6 weeks later. Visit 3 involved a telephone-based follow-up assessment 30 days after intervention. Of enrolled participants, 83% were retained across the three visits. Immediately following intervention, acceptability of RiskProfile was high (M = 4.4; SD = 0.6 on scale of 1 to 5); at 30-day follow-up, 89% of participants demonstrated accurate recall of key intervention messages. In the full analysis set of this single-arm trial, cigarettes smoked per day decreased from intervention to 30-day follow-up [11.3 vs. 9.8; difference = 1.5; 95% confidence interval (0.6-2.4); P = 0.001]. A personalized genetically informed risk tool was found to be highly acceptable and associated with a reduction in smoking, although the absence of a control group must be addressed in future research. This study demonstrates proof of concept for translating key basic science findings into a genetically informed risk tool that was used to promote progress toward smoking cessation.Prevention Relevance: This study demonstrates that personal genetic information can be incorporated into a risk feedback tool that was highly acceptable to current smokers and associated with reductions in smoking. These findings may pave the way for effectiveness and implementation research on genetically-informed behavior change interventions to enhance cancer prevention efforts. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32958583      PMCID: PMC7981287          DOI: 10.1158/1940-6207.CAPR-20-0328

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  40 in total

Review 1.  Genetics and smoking cessation improving outcomes in smokers at risk.

Authors:  Caryn E Lerman; Robert A Schnoll; Marcus R Munafò
Journal:  Am J Prev Med       Date:  2007-12       Impact factor: 5.043

2.  Web-based smoking-cessation programs: results of a randomized trial.

Authors:  Victor J Strecher; Jennifer B McClure; Gwen L Alexander; Bibhas Chakraborty; Vijay N Nair; Janine M Konkel; Sarah M Greene; Linda M Collins; Carola C Carlier; Cheryl J Wiese; Roderick J Little; Cynthia S Pomerleau; Ovide F Pomerleau
Journal:  Am J Prev Med       Date:  2008-05       Impact factor: 5.043

3.  Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1.

Authors:  Christopher I Amos; Xifeng Wu; Peter Broderick; Ivan P Gorlov; Jian Gu; Timothy Eisen; Qiong Dong; Qing Zhang; Xiangjun Gu; Jayaram Vijayakrishnan; Kate Sullivan; Athena Matakidou; Yufei Wang; Gordon Mills; Kimberly Doheny; Ya-Yu Tsai; Wei Vivien Chen; Sanjay Shete; Margaret R Spitz; Richard S Houlston
Journal:  Nat Genet       Date:  2008-04-02       Impact factor: 38.330

4.  Optimal Integration of Behavioral Medicine into Clinical Genetics and Genomics.

Authors:  William M P Klein; Colleen M McBride; Caitlin G Allen; Elva M Arredondo; Cinnamon S Bloss; Kimberly A Kaphingst; Amy C Sturm; Catharine Wang
Journal:  Am J Hum Genet       Date:  2019-02-07       Impact factor: 11.025

5.  Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation.

Authors:  Li-Shiun Chen; Timothy B Baker; Douglas Jorenby; Megan Piper; Nancy Saccone; Eric Johnson; Naomi Breslau; Dorothy Hatsukami; Robert M Carney; Laura J Bierut
Journal:  Drug Alcohol Depend       Date:  2015-06-23       Impact factor: 4.492

6.  Attitudes toward Precision Treatment of Smoking in the Southern Community Cohort Study.

Authors:  Nicole Senft; Maureen Sanderson; Rebecca Selove; William J Blot; Stephen King; Karen Gilliam; Suman Kundu; Mark Steinwandel; Sarah J Sternlieb; Shaneda Warren Andersen; Debra L Friedman; Erin Connors; Mary Kay Fadden; Matthew Freiberg; Quinn S Wells; Juan Canedo; Rachel F Tyndale; Robert P Young; Raewyn J Hopkins; Hilary A Tindle
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-06-03       Impact factor: 4.254

7.  Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD.

Authors:  Nancy L Saccone; Robert C Culverhouse; Tae-Hwi Schwantes-An; Dale S Cannon; Xiangning Chen; Sven Cichon; Ina Giegling; Shizhong Han; Younghun Han; Kaisu Keskitalo-Vuokko; Xiangyang Kong; Maria Teresa Landi; Jennie Z Ma; Susan E Short; Sarah H Stephens; Victoria L Stevens; Lingwei Sun; Yufei Wang; Angela S Wenzlaff; Steven H Aggen; Naomi Breslau; Peter Broderick; Nilanjan Chatterjee; Jingchun Chen; Andrew C Heath; Markku Heliövaara; Nicole R Hoft; David J Hunter; Majken K Jensen; Nicholas G Martin; Grant W Montgomery; Tianhua Niu; Thomas J Payne; Leena Peltonen; Michele L Pergadia; John P Rice; Richard Sherva; Margaret R Spitz; Juzhong Sun; Jen C Wang; Robert B Weiss; William Wheeler; Stephanie H Witt; Bao-Zhu Yang; Neil E Caporaso; Marissa A Ehringer; Tim Eisen; Susan M Gapstur; Joel Gelernter; Richard Houlston; Jaakko Kaprio; Kenneth S Kendler; Peter Kraft; Mark F Leppert; Ming D Li; Pamela A F Madden; Markus M Nöthen; Sreekumar Pillai; Marcella Rietschel; Dan Rujescu; Ann Schwartz; Christopher I Amos; Laura J Bierut
Journal:  PLoS Genet       Date:  2010-08-05       Impact factor: 5.917

8.  Return of individual genetic results in a high-risk sample: enthusiasm and positive behavioral change.

Authors:  Sarah M Hartz; Emily Olfson; Robert Culverhouse; Patricia Cavazos-Rehg; Li-Shiun Chen; James DuBois; Sherri Fisher; Kimberly Kaphingst; David Kaufman; Andrew Plunk; Shelina Ramnarine; Stephanie Solomon; Nancy L Saccone; Laura J Bierut
Journal:  Genet Med       Date:  2014-08-28       Impact factor: 8.822

Review 9.  The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysis.

Authors:  Gareth J Hollands; David P French; Simon J Griffin; A Toby Prevost; Stephen Sutton; Sarah King; Theresa M Marteau
Journal:  BMJ       Date:  2016-03-15

10.  Developing a common framework for evaluating the implementation of genomic medicine interventions in clinical care: the IGNITE Network's Common Measures Working Group.

Authors:  Lori A Orlando; Nina R Sperber; Corrine Voils; Marshall Nichols; Rachel A Myers; R Ryanne Wu; Tejinder Rakhra-Burris; Kenneth D Levy; Mia Levy; Toni I Pollin; Yue Guan; Carol R Horowitz; Michelle Ramos; Stephen E Kimmel; Caitrin W McDonough; Ebony B Madden; Laura J Damschroder
Journal:  Genet Med       Date:  2017-09-14       Impact factor: 8.822

View more
  2 in total

Review 1.  Are polygenic risk scores ready for the cancer clinic?-a perspective.

Authors:  Robert J Klein; Zeynep H Gümüş
Journal:  Transl Lung Cancer Res       Date:  2022-05

2.  In-vivo design feedback and perceived utility of a genetically-informed smoking risk tool among current smokers in the community.

Authors:  Jessica L Bourdon; Amelia Dorsey; Maia Zalik; Amanda Pietka; Patricia Salyer; Michael J Bray; Laura J Bierut; Alex T Ramsey
Journal:  BMC Med Genomics       Date:  2021-05-26       Impact factor: 3.063

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.